CANTOS Trial Findings

Date Posted: Sep 11, 2017

The CANTOS trial findings were presented in Barcelona in September 2017. Paul Ridker, the main author, has a long track record in the concept of inflammation being at the heart of coronary disease. It was he who put hsCRP (high sensitivity CRP) on the map as a marker of those with coronary disease who were going to do less well. He also ran the JUPITER study, which looked at the effect of high dose statin on the recurrence rates of MACE (Major atherosclerotic composite endpoints) and drew attention to the anti-inflammatory role of statins.

In this new study, he has taken an anti-inflammatory agent Canakinumab, a monoclonal antibody (anti-inflammatory agent normally used in certain childhood arthritis), $200,000 per year per patient (given free to the trial by the drug company), and shown that the drug improves the rate of MACE, but not of survival, a challenging finding. It caused this reduction without lowering LDL levels.

Interestingly, I was in the room in Barcelona when Dr Ridker outlined the results, and there was less of a crowd there than I thought there would be, and not many questions, although I heard the findings mentioned on RTE and BBC News on the way home; it is major news.

Eagle Lodge Cardiology Clinic | Directors: Dr. John Clarke

Company Registration Number: 2398076C